Document:

Exhibit 10.9

EXHIBIT 10.9

GEORGIA-CAROLINA BANCSHARES, INC.

DIRECTORS EQUITY INCENTIVE PLAN

formerly the

DIRECTORS STOCK PURCHASE PLAN

(as amended and restated effective October 26, 2009)

The Board of Directors of Georgia-Carolina Bancshares, Inc. (the “Company”) hereby amends and
restates the Directors Stock Purchase Plan, as amended (the “Plan”) for the purpose of offering
duly-elected directors of the Company and its wholly-owned subsidiary, First Bank of Georgia (the
“Bank”), including duly-appointed directors and advisory directors of Bank, the opportunity to
purchase shares of the Company’s Common Stock, $.001 par value (the “Common Stock”), and to
otherwise acquire shares of Common Stock as payment for services as a director.. The Company
originally authorized the sale and issuance of fifty thousand (50,000) shares of Common Stock
pursuant to the terms of this Plan. If the shares of Common Stock should, as a result of a stock
split, stock dividend, combination of shares, or any other change or exchange for other securities
by reclassification, reorganization, redesignation, merger, consolidation, recapitalization or
otherwise, be increased or decreased or changed into, or exchanged for, a different number or kind
of shares of stock or other securities of the Company or of another corporation, the number of
shares then remaining in the pool of shares reserved for this Plan shall be appropriately adjusted
to reflect such action.

1. Title of the Plan.

The title and name of the Plan shall hereafter be the Directors Equity Incentive Plan.

2. Purposes of the Plan.

The purposes of the Plan are (a) to provide Plan participants with a method of investing
directors’ fees in additional shares of Common Stock, (b) to provide Plan participants with
additional equity in the Company as payment for services as determined by the Board of Directors
from time to time, and (c) to provide the Company with additional funds for general corporate
purposes. No brokerage commissions, service charges, fees or other expenses will be paid by
participants in the Plan when purchasing shares of Common Stock through the Plan. All proceeds
from the sale of shares in the Plan will go to the Company and be used for general corporate
purposes.

3. Administration of the Plan.

The Plan will be administered by the Stock Option Committee of the Board of Directors of the
Company (the “Committee”), which may from time to time adopt rules and regulations not inconsistent
with the Plan for carrying out the Plan or for providing for matters not specifically covered
herein. Unless the Committee shall appoint another individual, the Secretary of the Company shall
serve as the Trustee of the Plan. The Trustee shall have the power and authority to establish such
procedures as the Trustee deems necessary or desirable to carry out and satisfy the provisions and
intent of the Plan.

 

 

 

4. Eligible Participants.

All duly-elected, non-employee directors of the Company and duly-elected, non-employee
directors and duly-appointed advisory directors of the Bank (each a “Director”) are eligible to
participate in the Plan during their period of service.

5. Method of Participation for Investing Directors’ Fees in Common Stock.

(a) Investment Election. A Director may elect to invest directors’ fees in Common
Stock at any time during the last seven (7) days of each calendar quarter, i.e. the last seven days
of each March, June, September, and December (the “Election Days”) by signing an authorization form
provided by the Company and returning it to the Trustee at 3527 Wheeler Road, Augusta, Georgia
30909. An authorization form may be obtained at any time from the Trustee at the same address.
Participation will be effective on the first day of the calendar quarter immediately following the
date of the Company’s receipt of the properly completed and signed authorization form. For
example, if the Company receives a completed and signed authorization form on March 29,
participation in the Plan will be effective on April 1. The authorization form directs the Trustee
to apply all of the participating Director’s board and committee fees (“Directors’ Fees”) to the
purchase of shares of Common Stock. An investment election under this Section 5(a) may not be made
by a Director at a time when such Director is in possession of material nonpublic information
regarding the Company or the Bank.

(b) Purchase Price of Plan Shares.

The price of each share of Common Stock (the “Purchase Price”) purchased with Directors’ Fees
shall be $2.00 less than the average closing market price of the Common Stock quoted on the
Over-the-Counter Bulletin Board (or other national quotation service) for the ten business days
prior to the last trade of the Company’s Common Stock reported prior to the Investment Date
(defined in Section 5(c) below); provided, however, that if the Company’s Common
Stock is not quoted on a national quotation service but is registered on a national securities
exchange, “Purchase Price” shall mean $2.00 less than the average closing market price of the
Company’s Common Stock on such national securities exchange for the ten business days prior to the
last trade of the Company’s Common Stock reported prior to the Investment Date; and further
provided, that if shares of the Company’s Common Stock are not quoted on a national quotation
service or registered on a national securities exchange, then the “Purchase Price” shall mean $2.00
less than the fair market value of the Company’s Common Stock on the Investment Date as determined
by the Committee, acting in good faith.

(c) Timing of Investments.

All investments by the Trustee will be made on the Investment Date except where and to the
extent that any applicable securities laws or other laws may require the suspension or curtailment
of purchases of shares of Common Stock. The “Investment Date” will be the first trading day of
each calendar quarter.

 

 

 

(d) Number of Shares to be Purchased.

The number of shares purchased will be based upon the amount of Directors’ Fees earned by the
participant since the last Investment Date plus any cash not utilized to purchase shares during the
previous quarter divided by the applicable Purchase Price. Each participant’s stock account will
be credited with the number of whole shares only equal to the total amount invested divided by the
Purchase Price (the “Purchased Shares”); provided, however, that the Committee may
elect to issue a stock certificate evidencing the Purchased Shares directly to a participant dated
as of the Investment Date in lieu of crediting such Purchased Shares to the participant’s stock
account. No fractional shares will be purchased.

(e) Reports to Participants.

Following each Investment Date, each participant in the Plan will receive a statement of his
or her account which will provide a record of the purchase made on the applicable Investment Date,
the total number of shares credited to the participant’s stock account as of the applicable
Investment Date and the balance of any uninvested cash.

(f) Stock Certificates.

Certificates for any number of whole shares credited to a stock account under the Plan will be
delivered to a participant upon his or her written request only. Otherwise, the number of shares
credited to a stock account under the Plan will be shown on the participant’s quarterly statements
of account. Certificates for fractions of shares will not be issued under any circumstances.
Shares credited to the stock account of a participant under the Plan may not be pledged. A
participant who wishes to pledge such shares must request that certificates for such whole shares
be issued in the participant’s name.

(g) Termination of Election to Invest Directors’ Fees in Common Stock.

To terminate a previous election made under Section 5(a), a participant must notify the
Secretary of the Company, in writing, of the termination of the investment election on any of the
Election Days. Termination notices received by the Secretary on a day other than one of the
Election Days will be effective as of the last day of the calendar quarter in which the written
notice is received by the Secretary. Upon such withdrawal by a participant, or upon termination of
the Plan by the Company, certificates for whole shares credited to the participant’s stock account
under the Plan will be issued to the participant and a payment by check will be made for the
balance of any uninvested cash. Automatic withdrawal from the Plan will occur upon a participant’s
resignation or removal from the Board of Directors of the Company and/or Bank. If a participant
withdraws from the Plan, whether voluntarily or due to termination of Board service, at a time when
the number of shares of Common Stock allocated to such participant’s stock account is ten or fewer,
the Trustee may elect to pay cash to the withdrawing participant equal to the value of the shares,
calculated pursuant to paragraph 5(b), in lieu of the allocated shares.

 

 

 

6. Payment of Annual Retainers and Other Compensation in Common Stock.

The Board of Directors of the Company may, in accordance with specific terms of issuance and
payment set forth in resolutions adopted by the Board from time to time, provide for the issuance
of shares of Common Stock to Plan participants in payment for any and all elements of Director
compensation, including but not limited to, annual retainers, service for chairing Board
committees, service bonuses, and other elements of compensation approved from time to time by the
Board.

7. Dividends. If the Company declares and pays a cash dividend on its Common Stock, the
Company will reinvest the dividends on the shares credited to a participant’s stock account under
the Plan. Any shares of Common Stock distributed as a result of a stock dividend or stock split on
shares credited to the stock account of a participant under the Plan will be added to the
participant’s stock account.

8. Voting of Plan Shares.

Participants will be permitted to vote the shares credited to the stock account of the
participant under the Plan. Such shares may be voted by proxy or in person at the applicable
shareholders’ meeting in the same manner as other shares of Common Stock.

9. Responsibility of the Company.

The Company, in administering the Plan, shall not be liable for any act done in good faith or
for any good faith omission to act, including without limitation, any claim of liability arising
out of failure to terminate a participant’s participation in the Plan upon such participant’s death
prior to receipt of notice in writing of such death, the prices at which shares are purchased for a
participant’s account, or fluctuations in the market value of the Common Stock. Any action taken
by the Board of Directors of the Company, or by the Stock Option Committee of the Board of
Directors of the Company, with respect to the implementation, interpretation or administration of
the Plan, shall be final, conclusive and binding.

10. Termination, Suspension or Modification of the Plan.

The Company may suspend, modify or terminate the Plan at any time. Notice of such suspension,
modification or termination will be sent to all participants.

11. General Matters.

Nothing in this Plan will be deemed to give any Director or such individual’s legal
representatives or assigns, or any other person or entity claiming under or through such
individual, any contractual or other right to participate in the benefits of the Plan. Nothing in
this Plan will be construed to constitute, or evidence, an agreement or understanding, express or
implied, by the Company and/or the Bank to retain a Director for any specific period of time.exv10w55

Exhibit 10.55

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,

MARKED BY ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE

SECURITIES AND EXCHANGE COMMISSION, PURSUANT TO RULE 24B-2 UNDER

THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

LICENSE AGREEMENT

This License Agreement (“Agreement”) is dated and effective as of the last signature date below
(“Effective Date”), and is made by and between the UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
(“CARDIFF”), a company incorporated under the laws of England and Wales whose address is 30-36
Newport Road, Cardiff, CF24 0DE, United Kingdom, CARDIFF UNIVERSITY (“the UNIVERSITY”), whose
principal office is at 30-36 Newport Road, Cardiff, CF24 0DE, and INHIBITEX, INC., a Delaware
corporation whose address is 9005 Westside Parkway, Alpharetta, GA 30004 (“Inhibitex”).

     In consideration of the mutual covenants and promises contained in this Agreement and
intending to be legally bound, the parties agree as follows:

ARTICLE 1. DEFINITIONS

	1.1.	 	“Affiliate” means any corporation or non-corporate entity that controls, is controlled by, or
is under common control with a Party to this agreement. A corporation or non-corporate
entity is to be regarded as in control of a corporation if it owns, or directly or indirectly
controls, at least fifty percent (50%) of the voting stock of the other corporation, or (i) in
the absence of the ownership of at least fifty percent (50%) of the voting stock of a
corporation or (ii) in the case of a non-corporate business entity, or non-profit corporation,
if it possesses, directly or indirectly, the power to direct or cause the direction of the
management and policies of such corporation or non-corporate entity, as applicable. For
purposes of this Agreement, an entity can be either an Affiliate or a Sublicensee, but not
both. If an entity meets the definition of “Affiliate,” it shall be treated herein as an
Affiliate for all purposes, even if it has also entered into a Sublicense.
	 
	1.2.	 	“Field” means any and all anti-viral uses including but not limited to prophylaxis, diagnosis
or treatment of a condition, infection or disease associated with a virus.
	 
	1.3.	 	“Licensed Patents” means the (i) patent applications listed in Appendix A, (ii) United States
patents that may issue from the patent applications listed in Appendix A and from divisionals
and continuations and continuations-in-part of such United States patents and patent
applications, (iii) all foreign counterparts of such patent applications, and all patents that
issue thereon anywhere in the world, including reexamined and reissued patents. Licensed
Patents shall also mean (iv) with respect to the matters described in clauses (i), (ii) and
(iii) above, all provisionals, renewals, re-examinations, patents of addition, supplementary
protection certificates, extensions, restorations of patent terms, letters of patent,
registration or confirmation patents and reissues of such patents or patent applications.

 Page 1 of 29 

 

	1.4.	 	“Licensed Product” means any product, service, or process in the Field, the manufacture, use,
or sale of which, but for the license granted herein, would infringe at least one Valid Claim.
	 
	1.5.	 	“Licensee” means Inhibitex, Inc. and its Affiliates.
	 
	1.6.	 	“Net Sales” means, subject to paragraph 3.1(c), the gross amount paid to and received by
Licensee as consideration for the sale by Licensee of Licensed Product in an arms length
transaction to any third party that is not an Affiliate, less the following deductions:

	 	(a).	 	 credits actually given for rejected, defective, recalled, or returned Licensed
Product or because of charge backs, refunds, rebates, or retroactive price reductions;
	 
	 	(b).	 	 freight and insurance costs and any other outbound transportation charges, if
separately stated on the invoice or purchase order or other document of sale paid by
the customer;
	 
	 	(c).	 	 excise taxes and customs duties included in the invoiced amount;
	 
	 	(d).	 	 other taxes (including but not limited to tariffs, duties, excises, sales,
value added, consumption or other taxes) imposed and paid in connection with the
production, sale, use, or delivery of Licensed Products (consistent with industry
practice); and
	 
	 	(e).	 	 customary cash discounts, rebates or charge backs actually granted, allowed,
taken or incurred in connection with the sale of such Licensed Product, or granted or
given to or imposed by governmental authorities and managed care systems (that is,
systems that integrate the financing and delivery of healthcare services to covered
members, including but not limited to, pharmacy benefit managers (PBMs), prescription
drug plans (PDPs), health maintenance organizations (HMOs), preferred provider
organizations (PPOs), independent practice associations (IPAs) and other similar
healthcare organizations), wholesalers and other distributors, buying groups, health
care insurance carriers, pharmacy benefit management companies, health maintenance
organizations or other institutions or health care organizations (including, without
limitation, any payments in respect of sales to any governmental authorities or with
respect to any government-subsidized program or managed care organization and any
discounts and rebates for any program for the benefit of low income, uninsured or other
patients who receive the opportunity to receive Licensed Products at discounted
prices).

	 	 	In the case of sales of Licensed Products other than at arm’s length (other than supplies of
Licensed Products to the UNIVERSITY) Net Sales will be equivalent to the price at which
Licensed Products would have been invoiced in a sale at arm’s length less deductions
referred to in (a) to (e) above. Transfers among Affiliates are not considered sales and
are not included in Net Sales; however the number of transfers shall be reported to CARDIFF
in the reports of sales described in Article 4 below.
	 
	1.7.	 	“Parties” means CARDIFF, the UNIVERSITY, and Inhibitex. Party means one of CARDIFF, the
UNIVERSITY, and Licensee.

 Page 2 of 29 

 

	1.8.	 	“Patent Expenses” means the reasonable actual and documented out of pocket documented costs
paid to third parties by CARDIFF in prosecuting and maintaining the Licensed Patents.
	 
	1.9.	 	“Sublicense” means a grant of all or part of the rights to Licensed Patents that are granted
to Licensee by this Agreement, made by (a) Licensee; (b) a person or entity that has licensed
such rights from Licensee; or (c) by a person or entity that has received such rights from a
person or entity that licensed such rights from Licensee.
	 
	1.10.	 	“Sublicensee” means any person or entity entering into a Sublicense.
	 
	1.11.	 	“Territory” means the world.
	 
	1.12.	 	“Valid Claim” means a claim in an unexpired patent or patent application included in the
Licensed Patents, so long as such claim shall not have been irrevocably abandoned or held
invalid in an unappealed or unappealable decision of a court or other authority of competent
jurisdiction; it being understood that, if a claim of a pending patent application has not
issued as a claim of an issued patent within eight (8) years after the original filing date of
the pending application containing such claim, such pending claim shall cease to be a Valid
Claim for purposes of this Agreement unless and until such claim becomes an issued claim of an
issued patent. If such claim later issues then royalties for sales, which but for a license,
would infringe the claim shall be paid for the period beginning on the original filing date of
the claim until such time the claim ceases to be a Valid Claim.

ARTICLE 2. GRANT OF LICENSE AND OPTION

	2.1.	 	Grant. Subject to the reservations in this Article and payment obligations in Article 3,
CARDIFF grants to Licensee the exclusive right and license under the Licensed Patents to make,
have made, use, import, offer for sale, and sell in the Territory, Licensed Products during
the term of this Agreement including Licensee’s right to grant sublicenses pursuant to
paragraph 2.3.
	 
	2.2.	 	Reservation of Rights.

	 	(a).	 	 The license granted in paragraph 2.1 is subject to a reserved, non-exclusive
license of the UNIVERSITY, transferable to its not-for-profit academic collaborators,
to practice the Licensed Patents in the Field, only for the purpose of non-commercial
scientific inquiry, academic research, and education. This reservation does not extend
to any research funded by any non-academic or for profit entity. Any materials within
the scope of the Licensed Patents sent to a not-for-profit academic collaborator
outside of the UNIVERSITY for use in the Field will be sent using a material transfer
agreement stating that the materials and results derived from them will be used solely
for not-for-profit academic purposes and that the materials will not be transferred to
any third party without the express written permission of the UNIVERSITY.

	2.3.	 	Sublicenses. Licensee may grant sublicenses of any and all rights granted to Licensee
herein, and Licensee may authorize its sublicensees to grant sub-sublicenses. Such
Sublicenses shall not contain terms and conditions that conflict with those included in this
Agreement. Licensee shall provide to CARDIFF a complete copy of all Sublicenses

 Page 3 of 29 

 

	 	 	within thirty (30) days after execution, subject to confidentiality terms acceptable to the
respective Sublicensee. The existence, terms and conditions of such sublicenses are the
confidential information of Licensee.

	 	(a).	 	 Licensee shall remain fully responsible for the operations of Sublicensees that
are relevant to this Agreement as if such operations were carried out by Licensee.
Licensee is responsible for payments owed to CARDIFF and triggered by activities of
Sublicensees such as milestone payments (Appendix D).
	 
	 	(b).	 	 No fees are owed directly to CARDIFF by a Sublicensee as a result of entering
into a Sublicense.
	 
	 	(c).	 	 Licensee shall include, or shall cause to be included, in all Sublicenses a
provision requiring the Sublicensee to indemnify CARDIFF and maintain liability
coverage to the same extent that Licensee is so required under this Agreement, and a
provision granting CARDIFF the right to audit Sublicensee to the same extent that
CARDIFF may audit Licensee hereunder.
	 
	 	(d).	 	 Upon termination of this Agreement by CARDIFF for any reason, all Sublicences
will terminate. In no event does CARDIFF have any obligations to a Sublicensee
whatsoever with respect to (i) any past, current, or future obligations Licensee may
have had, or may in the future have pursuant to such Sublicense, and (ii) any future
obligations to Sublicensee beyond those to Licensee in this Agreement.

	2.4.	 	No Other Obligations. Except as expressly stated in this Agreement, none of CARDIFF or the
UNIVERSITY faculty, staff, employees, or students are obligated to report or deliver to
Licensee or its Sublicensees under this Agreement any compounds, derivatives, technical
information, know-how, data, or other tangible materials of any kind related to the Licensed
Patents.
	 
	2.5.	 	New Inventions Outside the Field.

	 	(a).	 	 Option. If, during the term of this Agreement, Licensee first conceives of or
reduces to practice a new, patentable invention outside the Field, the manufacture,
use, or sale of which, but for a license, would infringe at least one Valid Claim (“New
Invention”), Licensee must inform CARDIFF of such New Invention in writing within sixty
(60) days of its conception or reduction to practice and CARDIFF hereby grants to
Licensee an option to acquire an exclusive, royalty-bearing, commercial license (i) to
Licensed Patents outside the Field only as necessary for Licensee to make, have made,
use, import, offer for sale and/or sell in the Territory the New Invention; and (ii) to
any and all of CARDIFF’s ownership interest (if any) in the New Invention (the “Option
Rights”). The period of Licensee’s option will begin on the date that Licensee
provides written notice to CARDIFF of the New Invention and will expire ninety (90)
days thereafter (“Option Period”).
	 
	 	(b).	 	 Exercise of Option. At any time during the Option Period, Licensee may
exercise the option by written notice to CARDIFF, whereupon each of the following shall
be deemed to have occurred effective as of the exercise of such option: (x) the
“Field” shall be deemed to include the New Invention; and (y) the “Licensed Product”
shall be deemed to include the New Invention and,

 Page 4 of 29 

 

	 	 	 	accordingly, the grant of rights under paragraphs 2.1 and 2.2 and 2.3 shall be
deemed to include right to develop and commercialize the New Invention.

	2.6.	 	No Implied License. The license and rights granted in this Agreement do not confer any
rights upon Licensee as to any patents or technology not specifically identified in this
Agreement as part of Licensed Patents.

ARTICLE 3. CONSIDERATION

	3.1.	 	Royalty for Sales by Licensee. For sales of Licensed Products by Licensee, or an assignee of
this Agreement, CARDIFF shall be paid the following royalties:

	 	(a).	 	 Royalty. Licensee shall pay CARDIFF a royalty of [*****] on the total Net
Sales of Licensed Products sold by Licensee, provided that if there is no Valid Claim
in a given country that would be infringed by Licensee but for the license granted
herein, then a royalty of [*****] is owed to CARDIFF on sales of Licensed Products in
such non-patent country, and further provided that no royalty is due in such non-patent
country for any period during which there is a competing product for sale (i.e. a
product which would infringe a Valid Claim if a claim existed in such non-patent
country). Only one royalty shall be paid to CARDIFF per Licensed Product regardless of
the number of Licensed Patents that would be infringed by the Licensed Product absent
the license granted herein. Further, only one Net Sale of a given Licensed Product
shall be subject to a royalty payment regardless of how many arms length transactions
may occur between manufacture of the Licensed Product and purchase by the final end
user. [*****].
	 
	 	(b).	 	 Calculation of Royalties. If Licensee’s making, having made, offer for sale
or sale of a Licensed Product would infringe rights of a third party but for a license,
then Licensee may reduce the royalty percentage owed to CARDIFF on Net Sales of such
Licensed Product by any reasonable royalty or other amounts actually paid to such third
party by Licensee on such sale of Licensed Product for such license, but under no
circumstances may Licensee reduce such royalty percentage by more than [*****] per
annum (and any unapplied amounts may be carried forward for credit as provided above in
subsequent years). For the avoidance of doubt, the Licensee shall calculate any
reduction in the royalty percentage annually and such percentage shall always be
applied to the full royalty due to CARDIFF under 3.1(a).
	 
	 	(c).	 	 Combination Product Royalties. A Combination Product means any pharmaceutical
product which consists of a Licensed Product and one or more other active compounds
and/or active ingredients. In the event a Licensed Product is sold as part of a
Combination Product, the Net Sales from the Combination Product, for the purposes of
determining royalty payments, shall be determined by multiplying the Net Sales of the
Combination Product, during the applicable royalty reporting period, by the fraction,
A/(A+B), where A is the average net sales price of the Licensed Product when sold
separately in finished form and B is the average net sales price of the other active
product(s) included in

 Page 5 of 29 

 

	 	 	 	the Combination Product when sold separately in finished form, in each case during
the applicable royalty reporting period or, if sales of both the Licensed Product
and the other active product(s) did not occur in such period, then in the most
recent royalty reporting period in which sales of both occurred. In the event that
such average net sales price cannot be determined for both the Licensed Product and
all other active products(s) included in the Combination Product, Net Sales for the
purposes of determining royalty payments shall be calculated by multiplying the Net
Sales of the Combination Product by the fraction of C/(C+D) where C is the
applicable cost of goods amount of the Licensed Product in the Combination Product
and D is the applicable cost of goods amount of the active product(s) included in
the Combination Product. In the event of any disagreement as to the respective
average net sales price or cost of goods amount in the Combination Product, these
amounts shall be determined by a three member panel of qualified independent third
parties, one chosen by each Party and the third chosen by the first two. The
determination of the panel shall be made within twenty (20) business days following
written submissions by the Parties and a one day oral hearing. The determination of
the panel shall be final and binding on the Parties and the Party whose aggregate
costs of goods calculation is deemed by the panel to be less accurate shall bear all
of the legal costs and expenses associated with such proceedings.
	 
	 	(d).	 	 Notwithstanding the foregoing, whether through agreement between the Parties or
through decision by the panel, the royalty due to CARDIFF on sales of Combination
Products shall not be reduced by more than [*****] of Net Sales of the Combination
Products.

	3.2.	 	Royalty for Sales by Sublicensee. Royalties received by Licensee from a Sublicensee are
subject to paragraph 3.4 and are included in the definition of “Sublicense Payment” in
Appendix C.
	 
	3.3.	 	Annual License Maintenance Fees. Licensee shall pay to CARDIFF an annual license maintenance
fee as set forth in Appendix B no later than thirty (30) days after each anniversary of the
Effective Date; provided, however that Licensee shall have no obligation to pay an annual
license maintenance fee in any year that royalty payments are greater than the Appendix B
amount. Only one annual license maintenance fee is due to CARDIFF by Licensee in any calendar
year regardless of the number of patents within the Licensed Patents, and regardless of the
number of Sublicensees.
	 
	3.4.	 	Sublicense Fees. In addition to other payments required under this Article 3, in the event
that Licensee grants a Sublicense under one or more of the Licensed Patents, Licensee agrees
to pay CARDIFF Sublicense Fees as set forth and defined in Appendix C. The payment shall be
made thirty (30) days following receipt by Licensee of the relevant payment from the
Sublicensee. Sublicense Fees are only due if and when Sublicense Payments are actually
received by Licensee from a Sublicensee. Notwithstanding the definition of Sublicense and
Sublicensee at paragraphs 1.09 and 1.10 above and paragraph 2.3(a), no Sublicense Fees are due
or payable to CARDIFF by Licensee arising from any sublicense granted by a Sublicensee or any
other transaction entered into between a third party and a Sublicensee of Licensee.

 Page 6 of 29 

 

	3.5.	 	Milestone Payments. Licensee agrees to make milestone payments to CARDIFF as set forth in
Appendix D. Each milestone payment is owed whether the milestone is achieved by Licensee or by
a Sublicensee. If the milestone is achieved by Licensee, Licensee shall inform CARDIFF within
thirty (30) days of the event and the payment shall be made within thirty (30) days of the
notice of each event being served to CARDIFF. If the milestone is achieved by a Sublicensee,
Licensee shall inform CARDIFF within sixty (60) days of Licensee’s knowledge of the event and
payment shall be made within thirty (30) days of notice of each event being served to CARDIFF.
	 
	3.6.	 	Reimbursement for Patent Expenses. Licensee shall reimburse CARDIFF for all un-reimbursed
Patent Expenses (in no event to exceed [*****] in the aggregate) incurred before the Effective
Date. Thereafter, Licensee shall reimburse CARDIFF for all un-reimbursed Patent Expenses
incurred for each patent or patent application within the Licensed Patents for which Licensee
is the only licensee of CARDIFF (excluding Sublicensees). For Licensed Patents where there
are one or more additional licensees of CARDIFF other than Licensee (excluding Sublicensees),
Licensee shall reimburse CARDIFF a pro rata share of Patent Expenses based upon the number of
aggregate licensees; for example, Licensee would reimburse CARDIFF for [*****] of Patent
Expenses incurred for a patent having one other direct licensee of CARDIFF. Upon entering into
the first additional license agreement for the Licensed Patents other than with Licensee
(excluding Sublicensees), CARDIFF shall reimburse Licensee for [*****] of Patent Expenses
incurred prior to the date of that license agreement. As used herein, un-reimbursed Patent
Expenses shall mean CARDIFF has not received, and has no right to receive, reimbursement of
such expenses from any third party. Licensee shall make such payments within sixty (60) days
of CARDIFF’s invoice date.

ARTICLE 4. REPORTS AND AUDITS

	4.1.	 	Progress Reports. Within sixty (60) days of each calendar year end, Licensee shall provide
CARDIFF with a written report detailing the current status of the development of a Licensed
Product by Licensee and/or its Sublicensees.
	 
	4.2.	 	Payment Reports. During the term of this Agreement, Licensee shall furnish, or cause to be
furnished, written reports to CARDIFF regarding Net Sales of Licensed Products and any
Sublicense Fees that include all applicable information identified in Appendix C and E.
Licensee shall provide these reports within sixty (60) days of each calendar quarter following
the first sale of Licensed Products or entering into a Sublicense (but, in the case of any
Sublicense, such reports shall be due within ninety (90) days of each calendar quarter
following the first sale of Licensed Products).
	 
	4.3.	 	Audit. Licensee shall keep, and shall cause Sublicensees to keep, accurate records in
sufficient detail such that the amount of any Sublicense Fee or royalty due and payable to
CARDIFF may be verified. During the term of this Agreement and for a period of one year
thereafter, Licensee shall permit CARDIFF or its qualified representatives to inspect, copy,
and audit its books and records, no more than once per calendar year, with respect only to
Sublicense Payments received or the sale of Licensed Products, upon reasonable notice and
during normal business hours. Such books and records include, but are not limited to,
invoice registers and original invoices; product sales reports; price

 Page 7 of 29 

 

	 	 	lists, sales ledgers; accounting general ledgers; sublicense and distributor agreements;
price lists; product catalogues and marketing materials; financial statements and income tax
returns; sales tax returns; and inventory and production records and shipping documents.
Such examination shall be made at CARDIFF’s expense. If such examination determines an
underpayment of ten percent (10%) or more in the amount of royalty or other payments due
CARDIFF for any year, then Licensee shall reimburse CARDIFF for reasonable out of pocket
costs associated with such examination or audit, including any professional fees.
Conversely, if such examination determines an overpayment was made by Licensee, such
overpayments will be refunded or credited against future amounts owed by Licensee. No
separate confidentiality agreement will be required between the Parties to conduct such an
examination or audit provided that any representatives of CARDIFF agree to be bound by
confidentiality terms no less restrictive than those set forth in Article 10 herein, and the
results of the audit shall be treated as Licensee’s Confidential Information. The Parties
agree that CARDIFF or its representative may keep a copy of all documents provided by
Licensee hereunder and all documents created by CARDIFF or its representative in connection
with such examination or audit for archival purposes.

ARTICLE 5. PAYMENTS

	5.1.	 	Payments and Due Dates. Licensee shall pay to CARDIFF all Sublicense Fees and royalties
attributable to the period covered by each payment report under paragraph 4.2 on the date such
royalty report is due. All other payments, if not otherwise specified in this Agreement,
shall be paid within thirty (30) days after the due date. All payments shall be made by wire
transfer to an account designated by CARDIFF, or in person, via U.S. mail or by commercial
carrier to Dr. Nick Bourne at the above registered CARDIFF address.
	 
	5.2.	 	Currency Conversion. All royalties shall be paid in U.S. dollars. If any Licensed Products
are sold for consideration other than dollars, the Net Sales of such Licensed Products shall
first be determined in the currency of the country in which such sales of Licensed Products
were made and then converted to dollars at a ninety (90) day trailing average published by the
Wall Street Journal (U.S. ed.) for conversion of the foreign currency into dollars on the last
day of the quarter for which such payment is due.
	 
	5.3.	 	Overdue Payments. Without prejudice to any other rights or remedies to which CARDIFF may be
entitled whether hereunder, in equity or at law, CARDIFF shall be entitled to charge interest
on any overdue amounts from the date on which payment became due until the date on which
CARDIFF received payment in full (whether before or after judgment has been obtained by
CARDIFF against Licensee) at the interest rate in force pursuant to the Late Payment of
Commercial Debts (Interest) Act 1998 at the time the interest becomes chargeable. Any payment
not made due to a bona fide dispute between the Parties shall not be considered an overdue
payment until such dispute is resolved in CARDIFF’s favor, at which point the interest due
will have accrued as of the original due date.

 Page 8 of 29 

 

	5.4.	 	Termination Report and Payment. Within sixty (60) days after the date of termination or
expiration of this Agreement, Licensee shall make a final report and payment to CARDIFF per
Articles 4 and 5, respectively.
	 
	5.5.	 	No Refunds or Credits. All amounts paid to CARDIFF by Licensee pursuant to paragraphs 3.3
and 3.5 shall be non-refundable. Any amounts paid to CARDIFF pursuant paragraphs 3.1, 3.2,
3.4, or 3.6 in error or subject to correction shall be refunded or credited against future
payments by Licensee.

ARTICLE 6. COMMERCIAL DILIGENCE

	6.1.	 	Commercial Diligence. Licensee shall use commercially reasonable efforts, directly or through
Sublicensees, to bring one or more Licensed Products to market. Satisfactory diligence by a
Sublicensee shall satisfy the diligence obligation of Licensee. Without prejudice to any
other rights or remedies to which CARDIFF and/or the UNIVERSITY may be entitled to whether
hereunder, at law or in equity, Licensee will use reasonable endeavours to advise CARDIFF and
the UNIVERSITY promptly if it becomes unlikely that it will be unable to meet its material
obligations hereunder.

ARTICLE 7. PATENT PROSECUTION AND MAINTENANCE

	7.1.	 	Patent Prosecution and Maintenance. Licensee shall be primarily responsible for prosecuting
and maintaining the Licensed Patents using patent counsel reasonably acceptable to both
Parties. CARDIFF and Licensee shall use reasonable endeavours to cause the inventors on the
Licensed Patents to meet their obligations of disclosure to the U.S. Patent Office. The
parties shall enter into a common interest agreement so that both may communicate freely with
patent counsel. Licensee shall promptly provide CARDIFF with copies of all filings and
correspondence pertaining to patent prosecution and maintenance activities so as to give
CARDIFF reasonable opportunities to advise and cooperate with Licensee and review and comment
on such patent applications and prosecution documents. Licensee shall consult with CARDIFF as
to the preparation, filing, prosecution, and maintenance of all Licensed Patents reasonably
prior to any deadline or action with the United States Patent & Trademark Office or any
foreign patent office. Licensee and CARDIFF agree to cooperate with each other during the
patent application and prosecution process. To the extent Licensee determines that it does
not desire to file a patent application in a certain country, Licensee shall notify CARDIFF in
writing of such country in which Licensee determines not to file a patent application.
CARDIFF may, at its own expense, file patent applications in those countries in which Licensee
determines not to file. Applications filed in such countries will be excluded from the
Licensed Patents; and the expenses therefore shall not be reimbursed by Licensee. Upon ninety
(90) days prior written notice, Licensee may advise CARDIFF that it no longer wishes to
continue to prosecute or maintain one or more Licensed Patents in a particular country.
CARDIFF may elect to continue prosecution and maintenance at its own expense or permit such
Licensed Patents in such

 Page 9 of 29 

 

	 	 	countries to be abandoned or lapse. If CARDIFF elects to continue, Licensed Patents in such
countries shall be removed from Licensed Patents.
	 
	7.2.	 	Interferences. Licensee will give CARDIFF prompt written notice upon the declaration of any
interference involving the Licensed Patents. The Parties shall cooperate in the interference
proceeding using counsel acceptable to both parties unless there is a Sublicense, in which
case the counsel shall be chosen by the Sublicensee. In the absence of a Sublicense, fees and
costs incurred in connection with the interference shall be deemed to be Patent Expenses and
shall be reimbursed as provided herein. Licensee may terminate its obligation to reimburse
for interference expenses upon ninety (90) days written notice, and the claims or patent at
issue shall be removed from the Licensed Patents in the United States.
	 
	7.3.	 	Patent Extension. Upon a Party’s request and at Licensee’s pro rata expense CARDIFF shall
apply to the patent office of a given country to have the normal term of any Licensed Patent
extended or restored under a country’s procedure for extending a patent term where such
extension relates to duration of patent prosecution of such patent application. Licensee
shall assist CARDIFF in its efforts to obtain such extension. If extended, Licensee shall be
obligated to make all payments due under this Agreement through the end of the extended patent
term. If after written notice Licensee affirmatively elects not to extend, CARDIFF may at its
own expense obtain such extension, and the license to the non-elected extended Licensed Patent
under this Agreement will expire upon expiration of the natural patent term. No other type of
extension of the term of patent rights or exclusive marketing rights shall be sought by
CARDIFF or any licensee of CARDIFF except with the prior written consent of Licensee, which
consent shall not be unreasonably withheld.

ARTICLE 8. REPRESENTATIONS, WARRANTIES, DISCLAIMER,
LIMITATION OF LIABILITY, INDEMNIFICATION, AND INSURANCE

	8.1.	 	CARDIFF Representations. Licensee relies on the following representations of CARDIFF in
entering into this Agreement. CARDIFF represents that as of the Effective Date:

	 	(a).	 	 CARDIFF is a registered proprietor of and applicant for the patent applications
listed in Appendix A;
	 
	 	(b).	 	 CARDIFF has not granted any rights in claimed subject matter of the Licensed
Patents in the Field to a third party;
	 
	 	(c).	 	 CARDIFF has not received any notice that a product or process of a third party
is alleged to infringe any issued patent or allowed claim in the Licensed Patents, and
CARDIFF has given no such notice to any third party;
	 
	 	(d).	 	 all test results relating to the subject matter disclosed in the Licensed
Patents, as well as any and all other data and information at CARDIFF relating to the
subject

 Page 10 of 29 

 

	 	 	 	matter disclosed in the Licensed Patents, if requested by Licensee, has been made
available to Licensee;
	 
	 	(e).	 	 CARDIFF is compliant with all of its own policies, and with any laws or
regulations of which non-compliance would be material to this Agreement; and
	 
	 	(f).	 	 after reasonable inquiry with Professor Chris McGuigan, CARDIFF is not aware of
any test results or data that has not been provided or disclosed to Licensee that would
reasonably be expected to have a material adverse impact on Licensee’s evaluation or
the development of the inventions disclosed in the Licensed Patents.

	8.2.	 	CARDIFF Covenants. CARDIFF covenants that during the term of this Agreement:

	 	(a).	 	 CARDIFF will not grant any rights in Licensed Patents in the Field and in the
Territory to a third party;
	 
	 	(b).	 	 CARDIFF will promptly notify Licensee in writing if it receives any notice that
any issued patent or allowed claim in Licensed Patents is invalid or unenforceable;
	 
	 	(c).	 	 CARDIFF will promptly notify Licensee in writing if it receives any written
notice wherein a product or process of a third party is alleged to infringe any issued
patent or allowed claim in the Licensed Patents; and
	 
	 	(d).	 	 CARDIFF will use reasonable endeavours to continue to be compliant during the
term of this Agreement with all of its own policies, and with any laws or regulations
material to this Agreement.

	8.3.	 	Licensee Representations. CARDIFF relies on the following representations of Licensee in
entering into this Agreement. Licensee represents that as of the Effective Date:

	 	(a).	 	 Licensee is compliant with all of its own policies and with any laws and
regulations of which non-compliance would be material to this Agreement.

	8.4.	 	Licensee Covenants. Licensee covenants that during the term of this Agreement:

	 	(a).	 	 Licensee will not use the Licensed Patents for any purpose other than as stated
within this Agreement;
	 
	 	(b).	 	 Licensee will not act as an agent of CARDIFF and/or the UNIVERSITY and not give
any indication that it is acting otherwise than as a principal and not make any
representation nor give any warranty on behalf of CARDIFF or the UNIVERSITY; and

 Page 11 of 29 

 

	 	(c).	 	 Licensee will use reasonable endeavours to commercialize Licensed Products
during the term of this Agreement.

	8.5.	 	Mutual Representations. The Parties each rely on the following representations in entering
into this Agreement. Each Party represents that as of the Effective Date:

	 	(a).	 	 it has the right, power and authority to enter into this Agreement and to
perform its obligations hereunder;
	 
	 	(b).	 	 it has taken all necessary corporate action on its part to authorize the
execution and delivery of this Agreement and the performance of its obligations
hereunder;
	 
	 	(c).	 	 it has obtained all necessary consents, approvals, and authorizations of all
governmental authorities and other entities required in connection with entering into
this Agreement, except for those the failure of which to obtain would not have a
material adverse effect; and
	 
	 	(d).	 	 the execution and delivery of this Agreement, including the grant of licenses
or Sublicenses hereunder, and the performance of such Party’s obligations hereunder do
not conflict with or violate or constitute a default of any requirement of applicable
laws or regulations or with any material contractual obligation of such Party.

	8.6.	 	` Mutual Covenants. Each Party covenants that during the term of this Agreement:

	 	(a).	 	 it will take all necessary corporate action on its part to authorize the
performance of its obligations hereunder;
	 
	 	(b).	 	 it will use commercially reasonable efforts to obtain all necessary consents,
approvals, and authorizations of all governmental authorities and other entities (other
than FDA and other comparable product approvals and product pricing approvals) required
in connection with performance of its obligations under this Agreement, except for
those the failure of which to obtain would not have a material adverse effect; and
	 
	 	(c).	 	 performance under this Agreement, including the grant of Sublicenses hereunder,
and the performance of each Party’s obligations hereunder will not conflict with or
violate or constitute a default of any requirement of applicable laws or regulations or
with any material contractual obligation of such Party.

	8.7.	 	Disclaimer of Warranties. EXCEPT AS DESCRIBED IN ARTICLE 8, CARDIFF AND UNIVERSITY DISCLAIM
ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, RELATING IN ANY WAY TO THE LICENSED
PATENT RIGHTS OR LICENSED PRODUCTS, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND LICENSEE AND ITS SUBLICENSEES ASSUME

 Page 12 of 29 

 

	 	 	THE ENTIRE RISK AND RESPONSIBILITY FOR THE SAFETY, EFFICACY, PERFORMANCE, DESIGN,
MARKETABILITY, AND QUALITY OF ALL LICENSED PRODUCTS. NOTHING CONTAINED IN THIS AGREEMENT
SHALL BE CONSTRUED AS EITHER A WARRANTY OR REPRESENTATION BY CARDIFF OR UNIVERSITY AS TO THE
VALIDITY OR SCOPE OF THE LICENSED PATENTS.
	 
	8.8.	 	Limitation of Liability. CARDIFF and UNIVERSITY assume no liability with respect to
infringement of any patent or other intellectual property right of third parties due to the
activities of Licensee or Sublicensees under this agreement (except with respect to any breach
of this Agreement by CARDIFF or UNIVERSITY). In no event will CARDIFF or UNIVERSITY, or its
regents, trustees, directors, officers, faculty, students, employees, consultants, and agents
(collectively “CARDIFF Indemnitees”) be responsible or liable for any direct, indirect,
special, punitive, incidental, or consequential damages or lost profits to Licensee or
Sublicensees, or any other individual or entity arising from the acts or omissions of Licensee
or Sublicensees regardless of legal theory (except with respect to any breach of this
Agreement by CARDIFF or UNIVERSITY). The above limitations on liability apply even though
CARDIFF or UNIVERSITY, or any CARDIFF Indemnitees, may have been advised of the possibility of
such damage. Licensee shall not make any statements, representations, or warranties, or
accept any liabilities or responsibilities whatsoever, with regard to CARDIFF or UNIVERSITY or
CARDIFF Indemnitees that are inconsistent with any disclaimer or limitation included in this
agreement.
	 
	8.9.	 	Indemnification. Except with respect to any breach of this Agreement by UNIVERSITY or
CARDIFF (for which UNIVERSITY or CARDIFF hereby indemnifies the Licensee): none of UNIVERSITY,
CARDIFF or CARDIFF Indemnitees shall have any liability to Licensee or Sublicensees or any
other person or entity for or on account of (and Licensee agrees and covenants, and agrees to
cause each Sublicensee to agree and covenant, not to sue UNIVERSITY or CARDIFF or any CARDIFF
Indemnitee in connection with) any injury, loss, or damage of any kind incurred by Licensee or
Sublicensees or any other person or entity, whether direct, indirect, special, punitive,
incidental, consequential or otherwise arising under any legal theory (and further excluding
without limitation any existing or anticipated profits or opportunities for profits lost by
Licensee or Sublicensees), directly arising out of or in connection with or resulting from (i)
any acts or omissions of Licensee or a Sublicensee relating to this Agreement, Licensee’s or a
Sublicensee’s use of the rights granted under the Licensed Patents, Licensee’s or a
Sublicensee’s Licensed Products, or any of Licensee’s or Sublicensees’ activities undertaken
hereunder; (ii) the production, use, or sale of the Licensed Products by Licensee or a
Sublicensee, or (iii) any advertising or other promotional activities of Licensee or a
Sublicensee with respect to either (i) or (ii). Licensee shall indemnify and hold UNIVERSITY
and each CARDIFF Indemnitee harmless against all claims, demands, losses, damages or penalties
(including but not limited to reasonable attorney’s fees and expenses at the pretrial, trial
or appellate level) to the extent they are made against any of UNIVERSITY or any CARDIFF
Indemnitee with respect to items (i) through (iii) above, whether or not such claims are
groundless or

 Page 13 of 29 

 

	 	 	without merit or basis (except with respect to any breach of this Agreement by UNIVERSITY or
CARDIFF). UNIVERSITY and CARDIFF shall indemnify and hold Licensee and each Sublicensee
harmless against all claims, demands, losses, damages or penalties (including but not
limited to reasonable attorney’s fees and expenses at the pretrial, trial or appellate
level) to the extent they are made against UNIVERSITY or CARDIFF, Licensee or a Sublicensee
in respect to breach of this any representation, warranty or covenant herein by UNIVERSITY
or CARDIFF, whether or not such claims are groundless or without merit or basis. The Parties
understand and agree that each Party’s indemnification for any of its respective breaches of
its representations, warranties, covenants and agreements under this Agreement shall include
indemnification for attorney’s fees and expenses.
	 
	8.10.	 	Indemnification Procedure. As a condition to the indemnification under this Agreement, an
indemnified entity (UNIVERSITY or CARDIFF Indemnitee, Licensee or a Sublicensee as applicable
 — each being an “Indemnified Entity”) that intends to claim indemnification under this
Article 8 shall promptly notify Licensee and Sublicensees or UNIVERSITY or CARDIFF, as
applicable (such indemnifying entity, the “Indemnitor”) of any liability or action in respect
of which the Indemnified Entity intends to claim such indemnification, and the Indemnitor
shall have the right to participate in, and, to the extent the Indemnitor so desires, jointly
with any other Indemnitor similarly noticed, to assume the defense thereof with counsel
selected by the Indemnitor; provided, however, that an Indemnified Entity shall have the right
to retain its own counsel, with the fees and expenses to be paid by the Indemnified Entity.
The indemnity obligations under this Article 8 shall not apply to amounts paid in settlement
of any loss, claim, damage, liability, or action if such settlement is effected without the
consent of the Indemnitor, which consent shall not be unreasonably withheld. The failure to
deliver notice to the Indemnitor within a reasonable time after the commencement of any such
action, to the extent such failure substantially impairs Indemnitor’s ability to defend such
action, shall relieve such Indemnitor of any such liability to the Indemnified Entity with
regard to such action under this Article 8. The Indemnified Entity, its employees, and
agents, shall cooperate fully with the Indemnitor and its legal representatives in the
investigation of any action, claim, or liability covered by this indemnification.
	 
	8.11.	 	Insurance. Licensee shall obtain and carry in full effect, and shall cause Sublicensees to
obtain and carry in full effect, insurance with coverage and limits, the nature and extent of
which shall be commensurate with those of similar companies in Licensee’s industry. Such
insurance will be written by an insurance company having a rating reasonably acceptable to
CARDIFF, will name CARDIFF and UNIVERSITY as an additional insured, and shall require thirty
(30) days written notice to CARDIFF prior to cancellation, endorsement or other policy change.
Within thirty (30) days of a request by CARDIFF, Licensee shall provide CARDIFF with
appropriate certificates of insurance satisfying the obligations of Licensee hereunder.

 Page 14 of 29 

 

ARTICLE 9. INFRINGEMENT

	9.1.	 	Notice. The parties shall report to each other in writing all suspected infringement of the
Licensed Patents. Should Licensee desire to negotiate with or file suit against a potential
infringer, it shall first provide to CARDIFF a written analysis setting out in pertinent
detail the grounds for infringement and its proposed legal strategy. Upon such notice,
CARDIFF shall permit Licensee to take action under paragraph 9.2.
	 
	9.2.	 	Enforcement. Subject to paragraph 9.1, Licensee, or a Sublicensee, shall have exclusive
authority to negotiate, license, file suit, or otherwise settle the matter without limitation.
Licensee shall employ counsel reasonably satisfactory to CARDIFF; Licensee and Sublicensee,
as applicable, shall inform CARDIFF of all material developments, and provide CARDIFF with
copies of all material correspondence and pleadings, subject to any protective order or
confidentiality obligations imposed on Licensee or Sublicensee, as applicable. Licensee and
Sublicensee, as applicable, shall be responsible for its expenses, except that CARDIFF shall
cooperate in all reasonable respects with Licensee’s or Sublicensee’s requests at Licensees or
Sublicensee’s expense. CARDIFF consents to be joined as a party, if necessary in order for
Licensee to proceed with a suit. CARDIFF will execute any documents and instruments necessary
or appropriate for Licensee or Sublicensee to exercise its rights under this Article. CARDIFF
may be represented by its own counsel in such proceedings at its own expense. Prosecution,
settlement, or abandonment of any proceeding shall be at Licensee’s or Sublicensee’s
reasonable discretion, provided that Licensee or Sublicensee must not grant any infringer any
rights to the Licensed Patents other than by sublicense pursuant to paragraph 2.3 of this
Agreement. Recoveries collected by Licensee or Sublicensee will be paid as follows: (a) to
Licensee or Sublicensee to reimburse its documented and reasonable out of pocket third party
costs and expenses incurred in such action; (b) to CARDIFF for its documented and reasonable
out of pocket third party costs and expenses incurred in assisting Licensee; and (c) the
remainder, if any, shall be treated as if it were Net Sales under this Agreement (if there is
no Sublicense) and as if the portion received by Licensee were a Sublicense Payment (if there
is a Sublicense).
	 
	9.3.	 	CARDIFF Enforcement. If CARDIFF wishes to proceed against a potential infringer where the
infringing process or product is outside the Field and if Licensee agrees in writing to allow
CARDIFF to proceed, CARDIFF shall have exclusive authority to negotiate, license, file suit or
otherwise settle the matter outside the Field. CARDIFF shall employ counsel reasonably
satisfactory to Licensee, inform Licensee of all material developments, and provide Licensee
with copies of all material correspondence and pleadings, subject to any protective order or
confidentiality obligations imposed on CARDIFF. CARDIFF shall be responsible for its own
costs and expenses, except that Licensee shall cooperate in all reasonable respects with
CARDIFF’s requests at CARDIFF’s expense. Licensee consents to be joined as a party if
necessary in order for CARDIFF to proceed with a suit. Licensee will execute any documents and
instruments necessary or appropriate for CARDIFF to exercise its rights under this Article.
Licensee may be represented by its own counsel in such proceedings at its own expense.
CARDIFF will be responsible for its own expenses. Recoveries collected by CARDIFF will be
paid as follows: (a) to CARDIFF to reimburse its documented and reasonable out of pocket
third party costs and expenses incurred in such action, (b) to Licensee for its

 Page 15 of 29 

 

	 	 	documented and reasonable out of pocket third party costs and expenses incurred in assisting
CARDIFF, and (c) the remainder, if any, shall be retained by CARDIFF. CARDIFF has the right
to grant nonexclusive licenses outside the Field in settlement of any permitted enforcement
action it initiates. Notwithstanding anything to the contrary contained herein, CARDIFF
hereby covenants and agrees that it will not grant any exclusive licenses outside the Field
with respect to the Licensed Patents without granting to Licensee a right of first refusal
whereby: (a) CARDIFF shall notify Licensee of all the material terms of such proposed
exclusive license, (b) CARDIFF shall provide to Licensee all of the proposed definitive
agreements with respect to such exclusive license, and (c) Licensee shall have ninety (90)
days following the satisfaction of the matters described in clauses (a) and (b) to accept or
reject such exclusive license on the basis of the terms described in clauses (a) and (b).
	 
	9.4.	 	Abandonment. A Party that has filed suit and thereafter elects to abandon suit does not
waive any of its enforcement rights under paragraphs 9.2 or 9.3. The rights of Licensee
include the right to abandon a suit or refrain from suit. Licensee’s abandonment or refraining
from suit does not give CARDIFF the right to proceed.

ARTICLE 10. CONFIDENTIALITY

	10.1.	 	Confidential Information. Pursuant to and for the purpose of complying with its obligations
under this Agreement (“the Purpose”), either Party may disclose to the other Party
confidential and proprietary information, technical data, trade secrets or know-how, including
but not limited to, research, product plans, products, markets, developments, inventions,
processes, formulas, technology, designs, drawings, engineering, marketing, distribution,
sales methods and systems, and sales and profit figures (the “Confidential Information”).
	 
	10.2.	 	General Defined Terms. The terms “Recipient” and “Provider” refer to Licensee, the
UNIVERSITY and CARDIFF in their capacity either as the recipient or the provider of
Confidential Information under this Agreement.
	 
	10.3.	 	Manner of Disclosure. The Provider may disclose the Confidential Information to the
Recipient, in writing, electronically, orally or by drawings or inspection of documents or
other tangible property for the Purpose.
	 
	10.4.	 	Non-Disclosure Obligation. In its capacity as Recipient, each Party agrees that for a
period of five (5) years from the date of disclosures received, that such Party will treat the
Confidential Information with reasonable care to avoid disclosure of the Confidential
Information to any person (natural or otherwise). A Recipient may disclose such Confidential
Information to (i) others within its organization pursuant to paragraph 10.7 and (ii) to third
parties; provided they enter into a confidentiality agreement no less restrictive than that of
this Article 10. A Recipient shall be generally liable for unauthorized disclosure or failure
to exercise such reasonable care, but a Recipient will not be so restricted with respect to
any Confidential Information which:

	 	(a).	 	 is in the public domain, not through a breach of this Agreement, at the time of
disclosure;

 Page 16 of 29 

 

	 	(b).	 	 after disclosure, becomes part of the public domain, except through breach of
this Agreement by the Recipient;
	 
	 	(c).	 	 the Recipient can establish by competent proof was legally in its possession at
the time of disclosure by the Provider;
	 
	 	(d).	 	 comes to the Recipient from third parties who are not under an obligation to
the Provider to maintain the confidentiality of that Confidential Information;
	 
	 	(e).	 	 is independently developed by employees of the Recipient without use of the
Confidential Information, as shown by competent proof;
	 
	 	(f).	 	 is approved for release by written authorization of the Provider; or
	 
	 	(g).	 	 subject to paragraph 10.5, disclosure is required by applicable law or
administrative order.

	10.5.	 	Required Disclosures. If the Recipient is required by applicable law or administrative or
judicial order to disclose Confidential Information, the Recipient shall give the Provider
prompt notice of such fact so that the Provider may attempt to obtain a protective order or
other appropriate remedy with respect to any such disclosure. The Recipient shall fully
cooperate with the Provider in connection with the Provider’s efforts to obtain any such order
or other remedy. If any such order or other remedy does not fully preclude disclosure, the
Recipient will make such disclosure only to the extent that such disclosure is legally
required.
	 
	10.6.	 	Limited Use. Acceptance of the Confidential Information by the Recipient gives the
Recipient the right and obligation to use the Confidential Information only for the Purpose in
accordance with this Agreement and does not give the Recipient any sort of license to, use of,
or any other rights in the Confidential Information.
	 
	10.7.	 	Internal Dissemination. Recipient’s internal dissemination of the Provider’s Confidential
Information is limited to those employees, officers, directors, and agents (or, where the
UNIVERSITY is the Recipient, those employees, officers, directors, and agents of the
UNIVERSITY) whose duties justify the need to know such Confidential Information. The
Recipient will make all necessary efforts to require such officers, directors, employees,
students and agents, who have been given access to and who shall receive disclosures of the
Confidential Information, to maintain the strictest secrecy under the terms and conditions of
this Agreement.
	 
	10.8.	 	Unauthorized Use. If any third party makes any unauthorized use or disclosure of the
Confidential Information under this Agreement, the Recipient shall notify the Provider and
cooperate in taking reasonable steps to protect the Confidential Information from further
unauthorized use or disclosure.
	 
	10.9.	 	Return of Information. Upon termination or expiration of this Agreement and upon request by
the Provider, the Recipient will promptly return to the Provider all

 Page 17 of 29 

 

	 	 	Confidential Information received from the Provider which is in tangible form or provide a
letter certifying as to its destruction..

ARTICLE 11. TERM AND TERMINATION

	11.1.	 	Term. Unless sooner terminated as otherwise provided herein, this Agreement begins on the
Effective Date and continues until expiration of the last to expire of the Licensed Patents or
patent extension as provided by paragraph 7.3.
	 
	11.2.	 	CARDIFF Right to Terminate. CARDIFF may, without prejudice to any of its other rights,
terminate this Agreement if Licensee:

	 	(a).	 	 fails to pay any undisputed amount when due under this Agreement, and fails to
make such payment after ninety (90) days written notice by CARDIFF;
	 
	 	(b).	 	 fails to deliver any report when due under this Agreement, and Licensee fails
to make such report after ninety (90) days written notice from CARDIFF; or
	 
	 	(c).	 	 materially breaches or defaults any other material obligation under this
Agreement other than by (a)-(b) above, and fails to cure such breach or default within
ninety (90) days after receipt of written notice by CARDIFF.

	11.3.	 	Licensee Right to Terminate. Licensee may, without prejudice to any of its other rights,
terminate this Agreement:

	 	(a).	 	 at any time with or without cause effective on ninety (90) days written notice
of termination; or
	 
	 	(b).	 	 if CARDIFF materially breaches or defaults any material obligation under this
Agreement and fails to cure such breach or default within ninety (90) days after
receipt of written notice by Licensee.

	11.4.	 	Effect of Termination. If this Agreement terminates for any reason under paragraphs 11.2 or
11.3, on the effective date of termination Licensee shall immediately cease practicing the
inventions claimed in Valid Claims of Licensed Patents and making, having made and selling the
Licensed Products, and shall return to CARDIFF, or deliver or destroy as CARDIFF directs, all
Confidential Information in its possession; provided, however, that (a) Licensee and
Sublicensee may continue to sell in the ordinary course of business for a period of one (1)
year reasonable quantities of Licensed Products that are in Licensee’s normal inventory, at
the date of termination if (i) all monetary obligations of Licensee to CARDIFF have been
satisfied and (ii) royalties on such sales, and any other payments, are paid to CARDIFF in the
amounts and in the manner provided in this Agreement and (b) Licensee and Sublicensee shall
continue to own all patents, know-how and other rights developed by such parties on and after
the Effective Date.
	 
	11.5.	 	Survival. Notwithstanding termination or expiration of this Agreement for any reason, the
following provisions shall survive:

	 	(a).	 	 Licensee’s payment obligations that are accrued and remaining unpaid or
unperformed prior to such termination;
	 
	 	(b).	 	 Articles 4,5,8.6, 8.7, 8.8, 10, 11.4, 11.5, 12, and 13

 Page 18 of 29 

 

	 	(c).	 	 Any cause of action or claim of a Party, accrued or to accrue, because of any
breach or default of this Agreement by the other Party.

ARTICLE 12. DISPUTE RESOLUTION

	12.1.	 	Non-binding Mediation. Except for the right of each Party to apply to a court of competent
jurisdiction for a temporary restraining order, preliminary injunction, or other equitable
relief, any and all claims, disputes or controversies arising under, out of, or in connection
with this agreement (including patent validity, claim for theft of trade secrets, unauthorized
disclosure of confidential information, damages, restitution, rescission or reformation, or
any combination of such remedies) that the Parties are unable to resolve within sixty (60)
days following written notice of a dispute including an attempt to resolve the dispute, will
be mediated through non-binding mediation in good faith as follows: The Party raising such
dispute shall promptly provide notice to the other Party of its claim, dispute or controversy
in a writing that describes in reasonable detail the nature of the dispute (“Dispute Notice”).
By not later than twenty (20) business days after the recipient has received the Dispute
Notice, each Party shall have selected for itself a representative who has the authority to
bind such Party, and shall additionally have advised the other Party in writing of the name
and title of such representative. These representatives shall meet in person and in good faith
attempt to resolve the dispute within sixty days of the Dispute Notice. If they fail to
resolve it, then by not later than twenty (20) business day after their meeting date, the
Parties shall each notify the other of two acceptable mediators and the representatives shall
promptly select and agree upon one commonly acceptable mediator for a mediation hearing.
Within thirty days thereafter, the Parties shall enter into good faith mediation and shall
share the costs of mediation equally; provided, however, that each Party shall pay its own
attorneys’ fees. If the representatives of the Parties do not resolve the dispute within
thirty (30) business days after the mediation hearing, the Parties shall be deemed to have
satisfied this requirement for mediation.
	 
	12.2.	 	CEDR. All disputes between any or all of the Parties arising out of or in connection with
this Agreement and not resolved through good faith non-binding mediation as set forth in
paragraph 12.1 above shall be referred to mediation in accordance with the CEDR model
mediation procedure. To initiate a mediation, a Party may give notice in writing to another
Party requesting mediation. The mediation shall commence not less than thirty (30) days after
the date of the notice requesting mediation.
	 
	12.3.	 	Continued Performance. The Parties shall continue to perform their respective obligations
under this Agreement during the resolution of any dispute under the provisions of this Article
12.

ARTICLE 13. MISCELLANEOUS

	13.1.	 	Assignment. This agreement, and the rights and obligations hereunder, shall not be assigned
by Licensee without the prior written consent of CARDIFF, such consent not to be unreasonably
withheld; except that this Agreement or rights and obligations hereunder

 Page 19 of 29 

 

	 	 	may be assigned by Licensee without consent to the acquirer of substantially all of the
assets of Licensee to which the assigned rights and obligations pertain. CARDIFF and the
UNIVERSITY shall be free to assign, novate or otherwise transfer any and/or all of their
rights or obligations hereunder and Licensee shall enter into such deed of assignment,
novation or transfer in connection herewith as CARDIFF and the UNIVERSITY require. No
assignment requiring consent will be effective unless the assignor has, no less than ten
(10) days before the effective date thereof, (i) delivered written notice of the transaction
to the other Parties; and (ii) caused the successor entity to deliver to such other Parties
the form of a written assignment and assumption by such successor of all of the assigned
terms and conditions of this Agreement, such assignment and assumption to be in form and
substance satisfactory to such other Parties.
	 
	13.2.	 	Entire Agreement, Amendment and Waiver. This Agreement, including its Appendices, contains
the entire understanding of the parties with respect to the subject matter of this Agreement
and supersedes any and all prior written or oral discussions, arrangements, courses of conduct
or agreements. This Agreement may be amended only by a written instrument executed by the
parties. The waiver of an obligation hereunder shall not constitute a waiver of any other
obligation, and shall not constitute a permanent waiver of that obligation.
	 
	13.3.	 	Force Majeure. No Party shall be considered in default or be liable for any delay in
performance or for any non-performance caused by circumstances beyond the reasonable control
of such Party, including but not limited to acts of God, explosion, fire, flood, accident,
strike or other labor disturbance, war (whether declared or not), terrorism, sabotage, order
or decree of any court or unforeseen or unanticipated action of any governmental authority, or
other causes, whether similar or dissimilar to those specified, that cannot reasonably be
anticipated or controlled by the Party who failed to perform. Performance is excused only for
the duration of the force majeure event and a commercially reasonable time thereafter.
	 
	13.4.	 	Notices. All notices required or desired to be given under this Agreement, and all payments
to be made to CARDIFF under this Agreement, shall be delivered to the parties in the manner
set out herein and at the addresses set forth in Appendix G, unless otherwise set forth in
this Agreement. Notices may be given (i) by hand, or (ii) by certified mail return receipt
requested, or (iii) by commercial carrier. Such notices or payments are effective upon
receipt by an employee, agent, or representative of the receiving Party authorized to receive
notices or other communications sent or delivered in the manner set forth above.
	 
	13.5.	 	Severability. If any one or more of the provisions of this Agreement is held by any court
of competent jurisdiction to be invalid, illegal or unenforceable, such provision or
provisions shall be reformed to approximate as nearly as possible the intent of the Parties,
and the validity of the remaining provisions shall not be affected; provided that such
reformation does not depart materially from the intent of the Parties.
	 
	13.6.	 	Governing Law. This Agreement shall be governed by and construed in all respects in
accordance with the laws of England and Wales and, subject to the provisions of Article 12,
the parties (1) submit to the exclusive jurisdiction of the courts of England and Wales and
(2) waive any right each may have to trial by jury.

 Page 20 of 29 

 

	13.7.	 	Damages. The Parties each hereby waive any right to receive punitive, consequential,
special or indirect damages relating in any way to this Agreement.
	 
	13.8.	 	Marking. Licensee shall place in a conspicuous location on any Licensed Product (or its
packaging where appropriate) made or sold under this Agreement a patent notice in accordance
with applicable laws.
	 
	13.9.	 	Export Controls. Licensee acknowledges that Licensed Products may be subject to U.S. laws
and regulations controlling the export of technical data, biological materials, chemical
compositions, computer software, laboratory prototypes and other commodities (“Technical
Data”). Licensee’s transfer of Technical Data may require a license from an agency of the
U.S. government or written assurances by Licensee that Licensee shall not export Technical
Data to certain foreign countries without prior approval of the U.S. government. CARDIFF
neither represents that an export license will not be required nor that, if required, such
export license shall issue.
	 
	13.10.	 	Implementation. Each Party shall, at the request of the other Party, execute any document
reasonably necessary to implement the provisions of this Agreement.
	 
	13.11.	 	Relationship of Parties. The Parties are independent contractors. There is no relationship
of principal to agent, master to servant, employer to employee, or franchiser to franchisee
between the Parties. No Party has the authority to bind another or incur any obligation on
its behalf.
	 
	13.12.	 	Agreement Conflicts. In the event of a conflict between this Agreement and an Appendix
attached hereto, the terms of this Agreement shall control.
	 
	13.13.	 	Advertising. Each Party shall not use (and shall prohibit its agents, Affiliates, licensees
and sublicensees from using) the names and marks of the other Party or any of its agents in
connection with any commercial activity under this Agreement without prior written consent.
Notwithstanding the foregoing, Licensee may use the name of CARDIFF and/or the UNIVERSITY in a
non-misleading fashion in (i) business plans, offering memoranda and other similar documents
for the purpose of raising financing for the operations of Licensee as related to the Licensed
Products; (ii) as required in sublicenses to vest CARDIFF and the UNIVERSITY’s interests as a
third party beneficiary, and (iii) as required in any securities reports required to be filed
with the Securities and Exchange Commission.

IN WITNESS WHEREOF, the parties hereto have caused this License Agreement to be executed by their
authorized officers or representatives on the date indicated below.

UNIVERSITY COLLEGE CARDIFF

 Page 21 of 29 

 

	 	 	 	 	 
	CONSULTANTS LIMITED	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	Name (print):

	 	 

	 	 
	 

	 	 	 	 
	Title:
	 	 	 	 
	 

	 	 	 	 
	Date:
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	INHIBITEX, INC.	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	 

	 	 	 	 
	Name (print):
	 	 	 	 
	 

	 	 	 	 
	Title:
	 	 	 	 
	 

	 	 	 	 
	Date:
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	CARDIFF UNIVERSITY	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	 

	 	 	 	 
	Name (print):
	 	 	 	 
	 

	 	 	 	 
	Title:
	 	 	 	 
	 

	 	 	 	 
	Date:
	 	 	 	 
	 

	 	 	 	 

 Page 22 of 29 

 

APPENDIX A

LICENSED PATENTS

	 	 	 	 	 	 	 	 	 
	Title	 	Priority Date	 	Status/Comments
	[*****]
	 	 	[*****]	 	 	 	[*****]	 

 Page 23 of 29 

 

APPENDIX B

ANNUAL LICENSE MAINTENANCE FEES (Paragraph 3.3)

     Licensee shall pay CARDIFF an Annual License Maintenance Fee of [*****]no later than thirty
(30) days after each anniversary of the Effective Date; provided, however that Licensee shall have
no obligation to pay an annual license maintenance fee in any year that royalty payments are
greater than the Appendix B amount. Only one annual license maintenance fee is due to CARDIFF by
Licensee in any calendar year regardless of the number of patents within the Licensed Patents, and
regardless of the number of Sublicensees.

 Page 24 of 29 

 

APPENDIX C

SUBLICENSE FEES (Paragraph 3.4)

	1.	 	Definitions. “Sublicense Payment” means a payment received by Licensee as direct
consideration specifically for the grant of a Sublicense of the Licensed Patents. For
purposes of paragraph 3.4 and this Appendix C, Sublicense Payments include, but are not
limited to, [*****].
	 
	 	 	Notwithstanding the foregoing, Sublicense Payment specifically excludes the following
payments received by Licensee from any Sublicensees: [*****].
	 
	2.	 	Sublicense Fees.
	 
	 	 	If Licensee enters into a Sublicense for Licensed Product, and if Licensee receives from that
Sublicensee any Sublicense Payments related to that Licensed Product, then Licensee shall pay
CARDIFF [*****] of such Sublicense Payments. A copy of the sublicense and a copy of any other
contract relating to consideration for Licensed Patents shall be provided to CARDIFF under
reasonable obligations of confidentiality.

 Page 25 of 29 

 

APPENDIX D

MILESTONE PAYMENTS (Paragraph 3.5)

	 	 	 	 	 
	1. Milestone Payments.	 	Payment (USD)
	a. [*****].*
	 	$	[*****]	 
	b. [*****].*
	 	$	[*****]	 
	c. [*****].*
	 	$	[*****]	 
	d. [*****].*
	 	$	[*****]	 
	e. [*****].*
	 	$	[*****]	 
	f. [*****].*
	 	$	[*****]	 

 

			
	*	 	Successful completion is defined as achieving the regulatory defined primary endpoint for each
trial

 Page 26 of 29 

 

APPENDIX E

ROYALTY REPORTS

     Each Royalty Report due under this Agreement shall provide the following aggregate information
per quarter for all Licensed Products sold by Licensee or Sublicensees.

	1.	 	Sales report by country sufficient for CARDIFF to determine specific volume of sales and
total Net Sales in each country;
	 
	2.	 	Number of units of each Licensed Product sold by Licensee or by Sublicensees;
	 
	3.	 	Total dollar amount subject to Royalty;
	 
	4.	 	Applicable Conversion Rate for Foreign Sales;
	 
	5.	 	Total dollars Converted to U.S. Dollars;
	 
	6.	 	Minimum Royalty Due, if applicable;
	 
	7.	 	Total Royalty Due;
	 
	8.	 	Names and Addresses of all Affiliates selling Licensed Product, Sublicensees and
Distributors; and
	 
	9.	 	Number of Licensed Products transferred between Affiliates.

 Page 27 of 29 

 

APPENDIX F

INSURANCE REQUIREMENTS

     Beginning on the date a first clinical trial is initiated incorporating a Licensed Product and
continuing for five years after the date of the last sale of a Licensed Product in the United
States, Licensee shall maintain a commercial general liability insurance policy that insures
Indemnitees and names Indemnitees as an additional insured for all claims, damages, actions, and
judgments mentioned in Articles 8.9 and 8.10 of this Agreement, and provides Indemnitees with
liability coverage in an amount no less than five million Dollars ($5,000,000) per occurrence,
subject to a reasonable aggregate amount per policy period.

     In the event that this Agreement terminates without the sale of any Licensed Product, and no
sale of Licensed Product is anticipated, the insurance required under this paragraph may be
discontinued.

 Page 28 of 29 

 

APPENDIX G

NOTICES

	 	 	 	 	 
	1.

	 	If to CARDIFF:
	 	Dr Nick Bourne
	 

	 	 	 	University College Cardiff Consultants Limited
	 

	 	 	 	30-36 Newport Road
	 

	 	 	 	Cardiff
	 

	 	 	 	CF24 0DE
	 
	 	 	 	 
	2.

	 	If to the UNIVERSITY:
	 	Mr Geraint Jones
	 

	 	 	 	Research and Commercial Division
	 

	 	 	 	Cardiff University
	 

	 	 	 	30-36 Newport Road
	 

	 	 	 	Cardiff
	 

	 	 	 	CF24 0DE
	 
	 	 	 	 
	3.

	 	If to Licensee:
	 	Dr. Joseph M. Patti, Chief Scientific Officer
	 

	 	 	 	Inhibitex, Inc.
	 

	 	 	 	9005 Westside Parkway
	 

	 	 	 	Alpharetta, GA 30004
	 

	 	 	 	Facsimile: (678) 746-0624
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Walt A. Linscott, Esq.
	 

	 	 	 	Thompson Hine LLP
	 

	 	 	 	One Atlantic Center, Suite 2200
	 

	 	 	 	1201 West Peachtree Street
	 

	 	 	 	Atlanta, GA 30309-3449
	 

	 	 	 	Facsimile: (404) 541-2905

 Page 29 of 29

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]